Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Named Patient Program for Providing Access to Olverembatinib (HQP1351) to Countries Where the Drug is Not Available

NCT05594758 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT05594758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05594758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Named Patient Program for Providing Access to Olverembatinib (HQP1351) to Countries Where the Drug is Not Available
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported